T1	Participants 101 151	patients with advanced or recurrent breast cancer.
T2	Participants 317 367	patients with advanced or recurrent breast cancer.
T3	Participants 950 979	221 patients were assessable.
T4	Participants 1361 1476	patients who were premenopausal, had no prior therapy, and were stage IV at diagnosis with an intact primary tumor.
T5	Participants 1775 1819	patients who had not received prior therapy.
